Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 34.25 USD 2.67% Market Closed
Market Cap: 4.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+48%
Revenue
Forecast
+3%
Operating Income
Forecast
+4%
Net Income
Forecast
+15%

Wall Street
Price Targets

CYTK Price Targets Summary
Cytokinetics Inc

Wall Street analysts forecast CYTK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTK is 75.71 USD with a low forecast of 41.41 USD and a high forecast of 126 USD.

CYTK Lowest Forecast
Wall Street Target
41.41 USD
21% Upside
CYTK Average Forecast
Wall Street Target
75.71 USD
121% Upside
CYTK Highest Forecast
Wall Street Target
126 USD
268% Upside
Lowest
Price Target
41.41 USD
21% Upside
Average
Price Target
75.71 USD
121% Upside
Highest
Price Target
126 USD
268% Upside
Cytokinetics Inc Competitors:
Price Targets
AGIO
Agios Pharmaceuticals Inc
52% Upside
NIOX
Niox Group PLC
18% Upside
AKBA
Akebia Therapeutics Inc
103% Upside
300676
BGI Genomics Co Ltd
7% Upside
AGIO
Agios Pharmaceuticals Inc
52% Upside
NIOX
Niox Group PLC
18% Upside
AKBA
Akebia Therapeutics Inc
103% Upside
300676
BGI Genomics Co Ltd
7% Upside
EXEL
Exelixis Inc
3% Downside
MIRM
Mirum Pharmaceuticals Inc
43% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
30% Upside
ACAD
ACADIA Pharmaceuticals Inc
31% Upside

Revenue
Forecast

Revenue Estimate
Cytokinetics Inc

For the last 8 years the compound annual growth rate for Cytokinetics Inc's revenue is -20%. The projected CAGR for the next 3 years is 184%.

-20%
Past Growth
184%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cytokinetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cytokinetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
What are analyst estimates?

See Also

Summary
CYTK intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYTK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYTK stock valuation using valuation multiples.
Wall Street Estimates
CYTK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYTK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYTK's stock price target?
Price Target
75.71 USD

According to Wall Street analysts, the average 1-year price target for CYTK is 75.71 USD with a low forecast of 41.41 USD and a high forecast of 126 USD.

What is Cytokinetics Inc's Revenue forecast?
Projected CAGR
184%

For the last 8 years the compound annual growth rate for Cytokinetics Inc's revenue is -20%. The projected CAGR for the next 3 years is 184%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.